Italian BioAg Firm Valagro launches $14 million production facility in Orangeburg County, SC see more
COLUMBIA, S.C. – Valagro, a producer of biostimulants and fertilizers for the agriculture industry, is launching its new production operations in Orangeburg County. The company’s $14 million investment is projected to create 47 new, high-skilled jobs.
Founded in 1980 and headquartered in the Abruzzo region of Italy, Valagro is a global leader in the world of biostimulants. The company specializes in the production and marketing of specialty nutrients for use in agricultural production and other industrial applications. Valagro operates through its 12 subsidiaries and owns a commercial network covering more than 80 countries worldwide. Providing innovative and effective solutions for plant nutrition and care, the company’s mission is to increase the quantity and quality of plants and harvested crops while enhancing productivity and reducing environmental impact.
Located at 397 Millennium Drive in Orangeburg, S.C., Valagro’s new, 65,000-square-foot Orangeburg County facility is expected to come online in the third quarter of 2019. Construction is expected to begin in the fourth quarter of 2018.
For more information on Valagro, visit the company’s website at https://www.valagro.com/en.
The Coordinating Council for Economic Development has approved job development credits, as well as a $100,000 Rural Infrastructure Fund grant to Orangeburg County to assist with the costs of building construction.
“The construction of this U.S. production facility greatly supports our ability to better serve some of the most strategically-important markets, such as the U.S., Canada and Mexico. This means fully implementing Valagro’s principle of putting the customer in the center; the new facility will allow us to improve our ability to meet customers’ needs by providing them with a wide range of sustainable and effective nutritional solutions.” –Valagro CEO Giuseppe Natale
“Today, we celebrate yet another international firm choosing to do business in South Carolina, a further testament to our business-friendly climate and well-trained workforce. I congratulate Valagro and Orangeburg County on this terrific new partnership and look forward to watching it thrive for years to come.” –Gov. Henry McMaster
“When a new business comes to South Carolina, it speaks volumes not only about our business climate, but also about our workforce. I am excited to see what the future has in store for Valagro and their new home in Orangeburg County.” –Secretary of Commerce Bobby Hitt
“We welcome Valagro to South Carolina and to Orangeburg County. Valagro is joining one of the state’s top industries, and we’re eager to share our agribusiness-friendly climate with this international company as it builds its new U.S. production facility.” –S.C. Agriculture Commissioner Hugh Weathers
“South Carolina Ports Authority welcomes Valagro to our state and looks forward to serving its import needs. The Port plays an important role in the international supply chains of manufacturers across our state, and we look forward to supporting their addition to our growing economy.” –S.C. Ports Authority President and CEO Jim Newsome
“Orangeburg County welcomes Valagro to our community. We are grateful they have chosen Orangeburg County as your first manufacturing facility in the U.S. It is a testament to our skilled workforce, location and pro-business environment. We thank Valagro for their investment in our county and our citizens.” –Orangeburg County Council Chairman Johnnie Wright Sr.
“I join with the Orangeburg City Council in welcoming Valagro, a leader in the production and marketing of biostimulants and specialty nutrients. Their commitment is a positive reflection of our workforce and will provide quality careers for our citizens. By creating these jobs, 47 families will benefit, and our community will continue to prosper. We look forward to working with the company and celebrating its success.” –Orangeburg Mayor Michael C. Butler
“We’re delighted that Valagro has selected Orangeburg County for its next facility. The company’s expansion into Orangeburg County is a boon for the local economy and workforce and further confirms South Carolina’s position as a strong competitor in attracting international companies looking to grow their business in the U.S.” –Central S.C. Alliance Chairman Mike Brenan
Industry subject matter experts to cover what businesses need to know about state industry see more
GREENVILLE, SC – February 14, 2018 – SCBIO will host a half-day program March 14, 2018 -- South Carolina Life Sciences Boot Camp: Essentials of a Growing Industry – to inform and update businesses and professionals from across the state on opportunities, trends and issues facing South Carolina’s fastest-growing industry segment.
To be held at the University of South Carolina’s Arnold School of Public Health in Columbia, the program will run from 8:30 a.m. until 12:30 p.m. and will feature a light breakfast followed by presentations from over half a dozen noted life sciences industry leaders. Confirmed presenters and their topics are:
- Burnie Maybank, Author of the SC Life Sciences Act; Partner, Nexsen Pruet, “Life Sciences industry Economic Development Incentives”
- Stephanie Yarbrough, Partner, Womble Bond Dickinson, “M&A 101 in the Life Sciences Space”
- Kathryn Cole Becker, Principal, Translational Science Solutions, “FDA 101 for Medical Devices”
- Jeff Stover, Partner, Haynsworth Sinkler Boyd, “IP Essentials for Life Sciences”
- John Osborne, Partner, Good Growth Capital, “Introduction to Life Science Innovation & Entrepreneurship”
- Public Policy Hot Topics – Speaker to be announced
Attendance is free to SCBIO members and employees of SCBIO member companies, and available for only $75 to Non-Members. Advance registration is required, and space is limited. To register, visit www.SCBIO.org/Events.
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.
SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations. SCBIO’s diverse membership is leading research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.
For additional information on SCBIO, visit www.SCBIO.org.
Mount Pleasant's FirstString Research completes $15MM Series B financing see more
FirstString Research, a clinical-stage biopharmaceutical company, announced today that it has completed a $15 Million Series B financing round. Led by Park West Asset Management LLC and Sophos Capital Management L.P., the Series B financing round brings FirstString’s total investor funding to over $27 Million.
In connection with the Series B financing, Tony Bartsh of Park West and Neal McConnell of Sophos have joined FirstString’s Board of Directors. “FirstString’s team has developed impressive data for Granexin® across a wide range of wound healing indications. We believe the Series B capital will allow FirstString to accelerate the development pipeline in several promising areas. We look forward to the initiation of two important studies in the first half of 2018” said Tony Bartsh.
“We are thrilled to have Tony and Neal join our Board,” said Dr. Gautam Ghatnekar, President & CEO and Co-Founder of FirstString Research. “They bring with them a wealth of biopharmaceutical experience and expertise. We believe that the Park West and Sophos investments provide significant credibility and validation to our innovative technology and clinical strategy. With this new funding, FirstString will be able to continue our extensive pipeline development and to advance our existing late-stage clinical programs toward approval. ”
Zylö Therapeutics is locating new operations in Greenville County, SC. see more
GREENVILLE, S.C. – Zylö Therapeutics, a developer of state-of-the-art technology for the pharmaceutical industry, is locating new operations in Greenville County. The company is expected to create 30 new jobs.
Zylö Therapeutics has developed an innovative sustained-release drug-delivery system that delivers traditionally hard-to-deliver therapeutic agents through topical administration. With more than 10 years of research and development, the second generation of this technology continues to improve, providing 24-hour sustained release of a variety of agents, including nitric oxide, curcumin, lidocaine and more.
Zylö Therapeutics is headquartered at the NEXT on Main facility at 101 North Main Street in Greenville, S.C. NEXT is a program of the Greenville Chamber of Commerce that currently supports more than 100 knowledge-based companies in Upstate South Carolina.
Zylö Therapeutics’ operations will soon include a lab facility, where formulation and product development work will be performed. Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.
“With the bulk of our scientists and advisors located in the Northeast corridor, we considered a variety of alternative locations, but Greenville represents a wonderful balance of small-town feel, sophistication, high growth and vibrancy. In addition, the city offers a wealth of start-up resources that will assuredly work to our advantage over time.” – Zylö Therapeutics CEO Scott Pancoast
“To see a company like Zylö Therapeutics choose to invest in our state and our people is an important sign to the business community around the world that South Carolina is the place to be. We’ve worked hard to create a pro-business environment and cultivate a highly-trained workforce, and those efforts continue to pay off.” –Gov. Henry McMaster
“The success of South Carolina’s booming life sciences industry continues to impress, and I congratulate Zylö Therapeutics on today’s tremendous announcement. Over the last two decades, we’ve seen a major transformation in South Carolina’s economy, and innovative companies like Zylö Therapeutics are responsible for it.” –Secretary of Commerce Bobby Hitt
“Greenville County encourages growth in the bioscience sector of our economy. We are proud to welcome Zylö Therapeutics to Greenville as part of our vibrant bioscience community that is pioneering state-of-the-art technologies at the forefront of modern medicine. We wish great success for Zylö Therapeutics.” –Greenville County Council Chairman H.G. “Butch” Kirven Jr.
“Greenville has become increasingly attractive to industry leaders in next-generation medical care, as innovative companies like Zylö Therapeutics seek environments that can help connect resources, support emerging technologies and supply a dedicated workforce. The City of Greenville is thrilled to welcome Zylö to our vibrant downtown and we look forward to being a part of their company’s growth.” –City of Greenville Mayor Knox White
“We are excited to welcome Zylö Therapeutics as the newest member of NEXT and the Greenville startup community. This high-impact, knowledge-based company further strengthens the more-than-150 companies within this vibrant, entrepreneurial ecosystem.” –NEXT CEO John Moore
FIVE FAST FACTS
- Zylö Therapeutics is locating new operations in Greenville County.
- The start-up is projected to create 30 new jobs.
- Zylö Therapeutics is a developer of patented, state-of-the-art technology for the pharmaceutical industry.
- Headquartered in Suite 315 at 101 North Main Street in Greenville, S.C., the company’s operations will include a laboratory facility focused on formulation and product development.
- Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.
HITACHI TO EXPAND ITS CLINICAL REPORTING AND ANALYTICS FOR DIAGNOSTIC IMAGING WITH THE ACQUISITION OF VIDISTARHitachi Healthcare Americas Corp. has entered an agreement to acquire Greenville, SC's VidiStar, LLC see more
Twinsburg, OH January 9, 2018 - Hitachi Healthcare Americas Corporation, a wholly owned subsidiary of Hitachi, Ltd. (TSE: 6501) and a leading provider of medical imaging modalities to hospital and ambulatory clients nationwide, today announced that it has entered into an agreement to acquire VidiStar, LLC, a Greenville, SC-based company focused on reinventing how doctors review and report on diagnostic exams to drive productivity, portability, and improved communication and clinical decision making. Hitachi expects that the acquisition of VidiStar will advance the company's informatics strategy and analytics capabilities to improve workflow and intelligence for physicians, particularly with those providers conducting diagnostic ultrasound examinations.
"VidiStar has developed a cloud-based diagnostic viewer and customizable structured reporting solution for medical imaging and clinical decision support. With VidiStar, physicians can interpret exams over the web and deliver improved visualization and timely results with the extended care teams.” said William Burns, Senior VP, Hitachi Healthcare Americas.
“We are very excited about VidiStar becoming part of the Hitachi team and believe this partnership will further our client’s ability to reduce inefficiencies in clinical and operational workflows. We will work together to create the next generation of healthcare informatics and analytics solutions so providers and healthcare professionals can take full advantage of the power of informatics." said Craig Walker, CEO of Vidistar.
“This acquisition will add significant talent and expertise in expanding our Healthcare Informatics business at Hitachi. As the healthcare market transitions from volume to value-based care, structured reporting and advanced analytics will play a critical role in enabling and supporting this transition.” said Yasuhiko Taniguchi, CEO of Hitachi Healthcare Americas.
Structured reporting can help standardize and improve the quality of clinical reports and streamline communication among care teams while reducing errors. Advanced analytics and data mining can help identify key value drivers, improve decision making, and ensure that providers and healthcare professionals are informed and efficient in their mission to deliver high quality care.
Upon completion of the transaction, VidiStar and its employees will become part of the Hitachi Healthcare Americas business group within Hitachi. VidiStar will maintain its current headquarters office in Greenville, SC.
About VidiStar, LLC
VidiStar, LLC is based in Greenville, SC (USA) and has developed a web-based diagnostic viewer and patented structured reporting solution (US Pat. No. 8,200,505) for medical imaging and clinical decision support. VidiStar's technology allows physicians and healthcare providers the ability to read and interpret diagnostic studies over the internet for timely interpretation, improved patient diagnosis, clinical decision support, and advanced patient data analytics and notification. VidiStar is a 2012 and 2013 Innovision Award Winner and a 2008 and 2010 SCLaunch Portfolio Company.
About Hitachi Healthcare Americas Corporation
Hitachi Healthcare Americas Corporation, located in Twinsburg, Ohio, a wholly owned subsidiary of Hitachi, Ltd. offers a broad range of diagnostic imaging equipment including MRI, CT and Ultrasound. Hitachi’s MRI, CT and Ultrasound technologies provide speed, comfort and quality for both physicians and patients alike and play an important role in the diagnosis and treatment of disease while driving social innovation into healthcare. Visit www.hitachihealthcare.com.
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges. The company’s consolidated revenues for fiscal 2016 (ended March 31, 2017) totaled 9,162.2 billion yen ($81.8 billion). The Hitachi Group is a global leader in the Social Innovation Business, and it has approximately 304,000 employees worldwide. Through collaborative creation, Hitachi is providing solutions to customers in a broad range of sectors, including Power / Energy, Industry / Distribution / Water, Urban Development, and Finance / Government & Public / Healthcare. For more information on Hitachi, please visit the company’s website at http://www.hitachi.com/.
Rhythmlink International, LLC today announced a new patent licensing agreement... see more
Rhythmlink International, LLC today announced a new patent licensing agreement with Dignity Health that includes broad coverage for improving and expanding brain health monitoring options for caregivers and patients. Dignity Health’s US Patent Number 9,345,418 was protected and commercialized by the Dignity Health Intellectual Property Office and covers an EEG Net with Transmission Capabilities. This proprietary technology allows quick and easy collection of EEG data and distribution to medical equipment and health care personnel for analysis and intervention. This device is easy to use allowing staff the ability to monitor the brain anywhere anytime maximizing workflow efficiencies and freeing up existing EEG Neurodiagnostic staff, or other cross trained professionals, to be more productive in the patient care setting. Read full article...